EXAS - Exact Sciences Corporation
| Previous Close | 88.12 |
| Open | 88.88 |
| Bid | 87.90 x 800 |
| Ask | 91.48 x 800 |
| Day's Range | 87.50 - 89.00 |
| 52 Week Range | 37.36 - 90.94 |
| Volume | 993,515 |
| Avg. Volume | 1,623,483 |
| Market Cap | 10.883B |
| Beta (3Y Monthly) | 2.96 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.18 |
| Earnings Date | Feb 21, 2019 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 91.91 |
- Motley Fool•22 hours ago
Could Exact Sciences Be a Millionaire-Maker Stock?
Sizzling growth. Impressive prospects. But are they enough for Exact Sciences to make you a millionaire in the future?
- Zacks•4 days ago
Analysts Estimate Exact Sciences (EXAS) to Report a Decline in Earnings: What to Look Out for
Exact Sciences (EXAS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- Zacks•5 days ago
Should You Invest in the Invesco DWA Healthcare Momentum ETF (PTH)?
Sector ETF report for PTH
- Motley Fool•8 days ago
The $100 Billion Investing Opportunity That Could Revolutionize Cancer Treatment
This exciting area of cancer research could turn into a huge industry. How can investors potentially profit?
- Markit•10 days ago
See what the IHS Markit Score report has to say about Exact Sciences Corp.
Exact Sciences Corp NASDAQ:EXASView full report here! Summary * ETFs holding this stock have seen outflows over the last one-month * Bearish sentiment is moderate and declining * Economic output for the sector is expanding but at a slower rate Bearish sentimentShort interest | PositiveShort interest is moderate for EXAS with between 5 and 10% of shares outstanding currently on loan. However, this was an improvement in sentiment as investors who seek to profit from falling equity prices reduced their short positions on February 6. Money flowETF/Index ownership | NegativeETF activity is negative. Over the last one-month, outflows of investor capital in ETFs holding EXAS totaled $4.09 billion. Additionally, the rate of outflows appears to be accelerating. Economic sentimentPMI by IHS Markit | NegativeAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is weak relative to the trend shown over the past year, however, and is easing. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to score@ihsmarkit.com.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.
- Motley Fool•13 days ago
Here's Why Exact Sciences Soared 42.8% in January
The diagnostics company's new marketing partner appears to be pulling its weight.
- PR Newswire•14 days ago
Exact Sciences schedules fourth-quarter, full-year 2018 earnings call
MADISON, Wis., Feb. 4, 2019 /PRNewswire/ -- Exact Sciences Corp. (EXAS) today announced that the company plans to release its fourth-quarter and full-year 2018 financial results after the close of the U.S. financial markets on Feb. 21, 2019. Following the release, company management will host a webcast and conference call at 5 p.m. ET to discuss financial results and business progress.
- Motley Fool•20 days ago
4 Things Exact Sciences Investors Should Know About 23andMe's New Cancer Test
The FDA recently allowed 23andMe to waltz back into Cologuard's territory.
- GlobeNewswire•21 days ago
Analysis: Positioning to Benefit within Rollins, Hospitality Properties Trust, Exact Sciences, Tenet Healthcare, Entergy, and Calithera Biosciences — Research Highlights Growth, Revenue, and Consolidated Results
NEW YORK, Jan. 28, 2019 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.
- GuruFocus.com•23 days ago
Exact Sciences Corp (EXAS) President and CEO Kevin T Conroy Sold $24.7 million of Shares
President and CEO of Exact Sciences Corp (NASDAQ:EXAS) Kevin T Conroy sold 304,397 shares of EXAS on 01/25/2019 at an average price of $81.27 a share.
- Zacks•26 days ago
Is a Beat in Store for AbbVie (ABBV) This Earnings Season?
AbbVie (ABBV) is likely to beat earnings in fourth quarter. Impressive sales of its key drug, Humira and strong growth of Imbruvica and Mavyret are expected to drive fourth-quarter sales.
- Zacks•last month
Exact Sciences (EXAS) Is Up 16.34% in One Week: What You Should Know
Does Exact Sciences (EXAS) have what it takes to be a top stock pick for momentum investors? Let's find out.
- InvestorPlace•last month
Microbot’s Products in Focus After Huge Gains by MBOT Stock
Even after a 308% jump yesterday and a further 33% gain as of this afternoon, Microbot Medical Inc. (NASDAQ: MBOT) stock is trading around $13.05 but has a market capitalization of just $40 million. Plus, with only 2.79 million shares of MBOT stock outstanding and 26% of its float being sold short, MBOT is either an easy four-bagger or a stock that will lose all of those gains in no time. ### Why Microbot Medical Stock Rose An independent in-vitro laboratory study validated Microbot's self-cleaning shunt (or SCS). The theory that SCS may eventually treat occlusion, or Traumatic Brain Injury, is coming closer to reality. * 8 Dividend Stocks With Growth on the Horizon The contract-research-services firm that carried out the study used glioblastoma cells from human brains to assess the performance of SCS. During the 30-day study, the firm had three main findings,according to Microbot : InvestorPlace - Stock Market News, Stock Advice & Trading Tips * Significant cell growth and accumulation in a non-operating SCS and * A significant inhibition in cell growth in the constantly operating SCS with very little to no cell attachment on the robotic brush (ViRob) and on the opening where the robotic brush (ViRob) operates. * The study also demonstrated that the Company's SCS has the ability to operate after cells had accumulated on the catheter holes and the robotic brush (ViRob). Importantly, multiple, previous clinical studies have found that declines of memory that occur after head injuries can be prevented by slowing the growth of brain cells. ### Platforms And Products That Could Boost MBOT Stock ViRob is one of the company's two main platforms. It's a miniature robot that moves around inside of the human body. ViRob can be controlled remotely and fits in blood vessels, the digestive tract and the respiratory system. If the study of SCS validates its clinical use, then it may be used to treat a number of ailments. Among the conditions that SCS could treat, according to MBOT, are hydrocephalus, or "water in the brain," which occurs in 1 in every 500 babies born in the U.S., and normal pressure hydrocephalus (NPH), which can occur after a head injury. It is estimated that over 700,000 Americans have NPH. The other main platform, TipCAT, is a flexible endoscope that may help doctors treat problems that occur within the body's tubular structures, including the colon, blood vessels, and the urinary tract. Finally, the Tip Catheter Colonoscope, or TCC, product could be used to facilitate endoscopies, a procedure that is done 15 million to 20 million times annually. If one or more of these products are approved by the FDA and then widely adopted, MBOT stock is likely to rally tremendously. ### Related Investments Investors who are interested in the biotechnology and medical-equipment sector can invest in names other than MBOT stock. Exact Sciences Corporation (NASDAQ: EXAS) is growing nicely, thanks to its Cologuard test, a product which screens for colon cancer. Approved by the FDA in August 2014, the product was recommended by the American Cancer Society. The company estimated that it generated total revenue of $454 million to $455 million last year, up 71% year-over-year. Medtronic plc (NYSE: MDT) is a medical appliances and equipment supplier and is far more established than Microbot. Its shares are down about 14% from their 52-week highs and are valued at 15.6 times MDT's forward price-earnings ratio, which is based on analysts' consensus 2019 earnings-per-share estimate. Medtronic stock fell recently because of worries over its acquisition of Covidien. This acquisition widens the company's market because Covidien makes products that are used by hospitals to provide acute care. Conversely, Medtronic's product portfolio focuses primarily on chronic diseases. ### The Bottom Line on MBOT Stock MBOT stock may or may not drop from its current levels. No one knows for sure. And yet , MBOT stock is still more than 50% below the level it reached in April 2016, when MBOT stock was trading around $36. Those who bought Microbot Medical stock at $5.00 or less are enjoying their tremendous gains, while those who were on the sidelines might want to watch MBOT stock for awhile before buying it. As of this writing, the author did not hold a position in any of the aforementioned securities. ### More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * 10 Companies That Could Post Decelerating Profits * 10 A-Rated Stocks the Smart Money Is Piling Into * Mizuho: 7 Long-Term Value Stocks to Buy Now Compare Brokers The post Microbot's Products in Focus After Huge Gains by MBOT Stock appeared first on InvestorPlace.
- Motley Fool•last month
3 Healthcare Stocks Still Raising Expectations
If you're worried about recent guidance revisions downward, here are three top stocks from the healthcare sector that recently raised their outlook.
- Motley Fool•last month
What Caused Exact Sciences Shares to Fall 19.1% in December
Shares of the molecular diagnostics company reverted to the mean last month, perhaps creating a tremendous buying opportunity for aggressive investors.
- Barrons.com•last month
Exact Sciences Stock Soars as Upbeat Forecast Raises Hopes
Exact Sciences’ best-known diagnostic test has achieved increasing sales, and one analyst sees more growth to come.
- Motley Fool•last month
Why Exact Sciences Soared Today
The molecular-diagnostics company's early look at Q4 and full-year 2018 revenue numbers revved up investors.
- Market Realist•last month
Three Healthcare Stocks Rallying Over 10% Today
Three Healthcare Stocks Rallying Over 10% Today ## Three healthcare stocks The broader market is trading in the green territory today but largely on a mixed note compared to the volatility in the previous couple of sessions. At 11:40 AM ET, the S&P 500 Index (SPY), NASDAQ Composite Index (QQQ), and Dow Jones Industrial Average were trading with 0.8%, 1.1%, and 0.6% gains. However, some healthcare stocks (XLV)(VHT)(IBB) were making huge moves today. Let’s take a look. ## Loxo Oncology Today before the market opened, the American pharmaceutical giant Eli Lilly and Company (LLY) announced the acquisition of Loxo Oncology (LOXO). According to the agreement between the two companies, Eli Lilly will acquire Loxo for $235.00 per share in cash, which translates into approximately $8.0 billion. After the news came out, Loxo stock surged nearly 66.0% to $232.12. ## Sage Therapeutics The biopharmaceutical firm Sage Therapeutics (SAGE) revealed positive results of the Phase 3 ROBIN Study today. The outcome of the study suggested a “significant improvement” in women with postpartum depression (or PPD) who were treated with its SAGE-217 drug for two weeks. This news boosted investors’ confidence, and SAGE stock surged 62.1% to a day high of $158.09. ## Exact Sciences The molecular diagnostics firm Exact Sciences (EXAS) said today that it expects its fourth quarter of 2018 revenue between $142.5 million and $143.5 million, which reflected about a 64% rise in its revenue from the fourth quarter of the previous year. In a press release, the company said that it “completed approximately 292,000 Cologuard tests during the fourth quarter of 2018,” up about 66% year-over-year. Plus, Exact Sciences noted, “Nearly 15,000 health care providers ordered Cologuard for the first time during the fourth quarter of 2018.” These positive developments drove EXAS stock to rally today to post a day high of $72.78, up 11.0% from its previous session’s closing price. Note that in 2018, LOXO, LLY, and EXAS rose 66.4%, 37.0%, and 20.1%, respectively, while SAGE fell 41.8%.
- American City Business Journals•last month
Exact Sciences' stock rises as company anticipates $455M in 2018 revenue
In 2018, the company experienced a 64 percent increase in completed Cologuard tests at approximately 934,000.
- Market Realist•last month
Why Exact Sciences Surged 12% Today
Why Exact Sciences Surged 12% Today ## Price movement On January 7, Exact Sciences (EXAS) rose 11.96% as compared to its previous closing price and reached $73.50 in the pre-market trading session on NASDAQ. This movement followed the company’s press release announcing preliminary revenue results for the fourth quarter of 2018 and fiscal 2018. According to the press release, Exact Sciences expects to report revenues in the range of $142.5 million and $143.5 million for the fourth quarter of 2018, a YoY rise of 64%. The company also expects to report revenues in the range of $454 million and $455 million for fiscal 2018, a YoY rise of 71%. This performance has been driven by the robust rise in demand for the Cologuard test indicated for screening adults for colorectal cancer. According to the press release, Exact Sciences reported total Cologuard volumes of 934,000 tests, a YoY rise of 64%. Based on its closing price on January 4, the company reported returns of 8.15% in the last week, -20.58% in the last month, and -14.55% in the last quarter. Exact Sciences also reported returns of 5.51% in the last half year, 17.59% in the last year, and 4.04% YTD. ## Analyst recommendations and target price for Exact Sciences The 12-month consensus analyst recommendation for Exact Sciences on January 7 is a “buy.” The 12-month consensus target price for the company is $88, which is 21.38% higher than its last closing price on January 4. The highest target price estimate for the company is $100 and the lowest target price estimate is $75. Out of the 13 analysts covering Exact Sciences on January 7, seven analysts have rated the company as a “strong buy,” three analysts have rated the company as a “buy,” and three analysts have rated the company as a “hold.”
- Barrons.com•last month
Exact Sciences Stock Soars, General Motors Gains and 5 More Monday Morning Movers
STOCKSTOWATCHTODAY BLOG Dow Jones Industrial Average futures were trading up slightly Monday morning after trading lower earlier as trade talks between the U.S. and China begin. Here are seven stocks making moves Monday morning: (EXAS) (EXAS) is up 10.
- CNBC Videos•last month
ls Cisco heading higher? Is Exact Sciences a takeover tar...
The "Halftime Report" traders take viewer questions.
